Exome Sequencing of Bilateral Testicular Germ Cell Tumors Suggests Independent Development Lineages¹,²

Sigmund Brabrand⁎,†,‡, Bjarne Johannessen⁎,†,³, Ulrika Axcrona⁴, Sigrid M. Kraggerud⁎,†, Kaja G. Berg⁎,†, Anne C. Bakken⁎,†, Jarle Bruun⁎,†, Sophie D. Fosså⁵, Ragnhild A. Lothe⁎,†, Gustav Lehne⁶ and Rolf I. Skotheim⁎,†

⁎Department of Molecular Oncology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; †Center for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway; ‡Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; §Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; ¯Department of Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

Abstract

Intratubular germ cell neoplasia, the precursor of testicular germ cell tumors (TGCTs), is hypothesized to arise during embryogenesis from developmentally arrested primordial germ cells (PGCs) or gonocytes. In early embryonal life, the PGCs migrate from the yolk sac to the dorsal body wall where the cell population separates before colonizing the genital ridges. However, whether the malignant transformation takes place before or after this separation is controversial. We have explored the somatic exome-wide mutational spectra of bilateral TGCT to provide novel insight into the in utero critical time frame of malignant transformation and TGCT pathogenesis. Exome sequencing was performed in five patients with bilateral TGCT (eight tumors), of these three patients in whom both tumors were available (six tumors) and two patients each with only one available tumor (two tumors). Selected loci were explored by Sanger sequencing in 71 patients with bilateral TGCT. From the exome-wide mutational spectra, no identical mutations in any of the three bilateral tumor pairs were identified. Exome sequencing of all eight tumors revealed 87 somatic non-synonymous mutations (median 10 per tumor; range 5-21), some in already known cancer genes such as CIITA, NEB, platelet-derived growth factor receptor a (PDGFRA), and WHSC1. SUPT6H was found recurrently mutated in two tumors. We suggest independent development lineages of bilateral TGCT. Thus, malignant transformation into intratubular germ cell neoplasia is likely to occur after the migration of PGCs. We reveal possible drivers of TGCT pathogenesis, such as mutated PDGFRA, potentially with therapeutic implications for TGCT patients.

Neoplasia (2015) 17, 167–174

Exome Sequencing of Bilateral Testicular Germ Cell Tumors Suggests Independent Development Lineages¹,²

Address all correspondence to: Rolf I. Skotheim, MSc, PhD, Department of Molecular Oncology, Institute for Cancer Research, P.O. Box 4953 Nydalen, 0424 Oslo, Norway. E-mail: rolf.i.skotheim@rr-research.no

¹This article refers to supplementary materials, which are designated by Supplementary Tables S1 to S4 and are available online at www.neoplasia.com.

²Grant support: The study was funded by grants from the Comprehensive Cancer Center at Oslo University Hospital, South-Eastern Norway Regional Health Authority (B.J. was financed as a PhD student from the Project No. 2012067 grant to R.I.S.; Project 2008132 grant to S.M.K. and R.A.L.) and the Norwegian Cancer Society (grants to R.I.S., G.L., and R.A.L.) and partly supported by the Research Council of Norway through its Centers of Excellence funding scheme (Project No. 179571). Storage of computer files has been possible by allocations from NorStore (Project NS9013K). Conflict of interest: The authors declare no conflict of interest.

³Equal contribution.

Received 4 December 2014; Accepted 8 December 2014

© 2014 Neoplasia Press, Inc. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by/3.0/).

1476-5586/15

http://dx.doi.org/10.1016/j.neo.2014.12.005
Introduction
The incidence of testicular germ cell tumors (TGCTs) has increased considerably during the last 50 years and is currently the most frequent malignancy in men aged 15 to 44 years in the Western developed world [1]. TGCTs evolve from the precursor intratubular germ cell neoplasia unspecified (also known as carcinoma in situ), which is hypothesized to originate in utero from developmentally arrested primordial germ cells (PGCs) or gonocytes (GCs) [2]. In early embryonal life, PGCs migrate from the yolk sac to the dorsal body wall where the cell population separates before colonizing the genital ridges, the precursors of the gonads [3]. However, it is unsettled whether malignant transformation occurs before or after this separation.

To our knowledge, whole-genome or exome sequencing data from TGCT has never been reported [4–6]. Besides some reports on KIT mutations in both bilateral and unilateral TGCTs [7–10], the knowledge on gene mutations in TGCT as such is sparse [11]. In a recent exome sequencing study of intracranial germ cell tumors, mutations involving the KIT/RAAS signaling pathway were found in more than 50% of the cases [12]. A monoclonal origin of bilateral TGCT has been proposed based on the identification of substantial concordance of selected KIT mutations among pairs of bilateral TGCTs [10]. Nevertheless, these are data from only one single gene that also frequently carries identical mutations in tumors from different patients. As such, variants in a mutational hotspot in KIT will not prove monoclonality of bilateral TGCT. Principally, many molecular characteristics can be used to explore the clonality of bilateral TGCT, including genetic and epigenetic changes and expression of miRNA, mRNA, and proteins. Among these, changes in the DNA sequence are likely to be the most stable and as such suitable for clonality analyses.

Here, we report an exome-wide approach to explore the putative concordance in somatic mutations between bilateral TGCTs, revealing their monoclonal or polyclonal origin. We hypothesize that the occurrence of malignant transformation and associated somatic mutations in PGCs at a pre-separation stage would reflect in identical somatic mutations in subsequent bilateral TGCTs. By comparing the somatic exome-wide mutational spectra of bilateral tumor pairs, we were able to reveal their mutual diversity, opposing the notion of a monoclonal origin. Furthermore, as this is the first exome sequencing analysis of TGCT, we also provide new insights into the general mutational spectra of this malignancy.

Materials and Methods

Patients and Tissue Samples
Seventy-six patients diagnosed with germ cell cancer during 1969 to 2011 and who fulfilled the inclusion criteria of bilateral TGCT or extragonadal germ cell tumor (EGCT) in combination with TGCT were recruited from The Norwegian Radium Hospital, Oslo University Hospital registry. Only patients with available fresh frozen or formalin-fixed paraffin-embedded (FFPE) samples from tumor and normal tissues were eligible. The study was approved by Regional Committee for Medical and Health Research Ethics South-East D (2011/1588). All patients eligible for exome sequencing and alive at the time of study inclusion signed an informed consent formula.

All fresh frozen and most of the FFPE tissue samples were available from established study or diagnostic biobanks at The Norwegian Radium Hospital, Oslo University Hospital. The remaining FFPE tissue samples were obtained from 13 different diagnostic tissue biobanks in Norway. Fresh frozen and FFPE tumor tissue samples were obtained from radical/partial orchiectomy, open surgical biopsy, or retroperitoneal/mediastinal/supraclavicular surgery. Fresh frozen and FFPE normal samples were obtained from blood/fibroblasts (exome sequencing series) and spermatocord (extended series), respectively. Sections from all samples (exome sequencing and extended series) were stained with hematoxylin and eosin and evaluated by an experienced uropathologist. Hematoxylin and eosin–stained sections from all normal tissue samples in the extended series were reevaluated to ensure absence of spermatocord tumor infiltration. All matched tumor-normal pairs in the exome series were genotyped with the AmpFLSTR Identifiler PCR Amplification Kit (Applied Biosystems by Life Technologies, Thermo Fisher Scientific, Waltham, MA) to confirm that each pair was obtained from the same individual.

Nucleic Acid Isolation
The phenol/chloroform extraction method was applied to isolate DNA from all fresh frozen samples (exome sequencing series) [13], except for tumor II of patient 1, where the QIAamp DNA Mini Kit was used (Qiagen, Hilden, Germany). DNA from FFPE samples (extended series) was obtained from 4 × 25 μm tissue sections collected from each selected FFPE block and was isolated using QIAamp DNA Mini Kit (Qiagen) according to the manufacturer’s protocol except from an initial deparaffinization step. The extracted DNA was eluted in a 200-μl volume and the DNA concentration was quantified on a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific).

Exome Sequencing
Genomic DNA from eight tumors and five normal samples were analyzed by exome sequencing. DNA libraries (1050 ng input) were constructed according to the manufacturer’s instructions in the Illumina TruSeq DNA Sample Preparation Guide, Rev. C (Illumina, San Diego, CA). Libraries were enriched according to the TruSeq Enrichment Guide, Rev. J (Illumina) to create exome captured libraries. Cluster generation was carried out by the TruSeq PE Cluster Kit v2 (Illumina) and the templates were multiplexed on Illumina Genome Analyzer IIX flow cells. All samples were sequenced twice in two independent runs on the Illumina Genome Analyzer IIX platform with the TruSeq SBS Kit v5 (Illumina) and the sequence data were merged to increase the total coverage.

Polymerase Chain Reaction and Sanger Sequencing
Selected loci were amplified by polymerase chain reaction (PCR) and sequenced by Sanger sequencing. DNA from tumor and normal tissues was amplified in a 10-μl reaction volume containing 10 × PCR buffer with 15 mM MgCl₂ (Qiagen), dNTP mix, HotStarTag DNA Polymerase (Qiagen), and oligonucleotide primers (Eurogentec, Seraing, Belgium). Primer-specific annealing temperatures were used for PCR amplification (Supplementary Table S1); 100 ng of DNA from FFPE samples and 50 ng of DNA from fresh frozen samples were amplified 40 and 30 cycles, respectively, before purification of PCR products by adding 3 μl of ExoProStar 1-step (GE Healthcare, Little Chalfont, United Kingdom) to each sample. The subsequent sequence reaction was carried out using the BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems by Life Technologies, Thermo Fisher Scientific) before purification of
sequence products by the BigDye X Terminator Purification Kit (Applied Biosystems by Life Technologies, Thermo Fisher Scientific). Capillary electrophoresis was performed on an ABI 3730 DNA Analyzer (Applied Biosystems by Life Technologies, Thermo Fisher Scientific). The electropherograms were visualized using the Sequencing Analysis Software v5.3.1 (Applied Biosystems by Life Technologies, Thermo Fisher Scientific) and scoring of sequences was interpreted independently by two qualified persons. All identified mutations were proven as somatic and confirmed by unidirectional sequencing (forward or reverse primers) in two independent rounds of PCR amplification.

Data Analysis

Paired-end sequencing reads of length 100 bp were aligned to the reference genome GRCh37 with the Burrows-Wheeler Aligner, version 0.6.2 [14]. Alignments were converted from sequence alignment map files to the binary alignment map (BAM) format with Picard, version 1.61 [15] and subsequently sorted and indexed using SAMtools, version 0.1.18 [16]. The Picard toolbox was applied to remove duplicates (MarkDuplicates) and for adding read group information (AddOrReplaceReadGroups) to the BAM headers.

With Picard, version 1.61 [15] and subsequently sorted and indexed alignment map files to the binary alignment map (BAM) format version 0.6.2 [14]. Alignments were converted from sequence reference genome GRCh37 with the Burrows-Wheeler Aligner, version 1.1.4 [19] and indels by the SomaticIndelDetector tool from GATK. Output BAM files were sorted and indexed by Picard. To quality scores were recalibrated by the BaseRecalibrator tool from GATK. Indels in repeat regions that are likely to be introduced by sequencing errors were filtered out of the call set. ANNOVAR, version 2013-02-21, was used to appropriately annotate candidate variants [21]. Only mutations with no (zero) variant reads in normal tissue were accepted. The default coverage efficiency threshold in the MuTect algorithm (≥ 14 and ≥ 8 reads in tumor and normal samples, respectively) was applied to dichotomize the discovered mutations (Supplementary Tables S2A and S2B). Functional impact of selected mutations was evaluated \textit{in silico} by Mutation Assessor [22].

Results

A total of 76 patients with bilateral TGCT or EGCT and TGCT was included in the present study. Exome sequencing of tumor and normal samples was performed in five patients with bilateral TGCT. In three of these patients, both tumors were available (six tumor samples), whereas only one tumor was available in each of the remaining two patients (two tumor samples). In total, exome sequencing was performed in 13 samples (eight tumor and five normal samples; Table 1). Targeted analyses of selected mutated genes were carried out in an extended series of 71 patients by direct Sanger sequencing (Table 2).

Between 9.1 and 73.8 million sequence reads were generated for each deep-sequence sample, yielding a median coverage of 30.9 (range 4.6-48.9). Exome sequencing of tumor specimens revealed 297 somatic single-base substitutions (SBSs) and 16 somatic indels (Supplementary Tables S2A and S2B). The median number of SBSs and indels were 37 (range 24-53) and 1 (range 0-9), respectively. Among the overall 313 mutations, 78 were non-synonymous SBS (median 8, range 5-20) and 9 were non-synonymous indels (median 0, range 0-7; Table 1). The median frequency of somatic non-synonymous mutations (SBS + indels) per tumor reached merely 10

Table 1. Patients’ Demographics and the Identified Genes with Somatic Non-Synonymous Mutations for the TGCT Series Analyzed by Exome Sequencing

| Patient ID | Tumor ID | Age at Diagnosis of TGCT (Years) | Histology | Amount of Tumor Tissue in Samples (%) | Number of SBS | Number of Non-Synonymous SBS | Number of Indels | Number of Non-Synonymous Indels | Total Number of Non-Synonymous Mutations | Non-Synonymously Mutated Genes |
|------------|----------|----------------------------------|-----------|--------------------------------------|---------------|-----------------------------|-----------------|-------------------------------|--------------------------------------|----------------------------------|
| 1 I        | 31       | Sem *                            | 85        | 85                                    | 37            | 5                           | 0               | 0                             | 5                                    | ANK2, ANKR036, CD40LG, PTPRA, ZNF569 |
| 1 II       | 33       | Sem                              | 90        | 42                                    | 11            | 1                           | 0               | 1                             | 11                                   | BMP1, CSF1, CNTF, GPN1, LIF, LOTS2, MAP1LC3C, NOL5, PDE1A, TNFR1, TUBGCP6, DNAAF1, JMY, LIPA, PCDHB9, PDXDC1, PKD1L3, POL2R2, SDR54A, TBC1D16, TC25, VSIG1, WD866, ZNF253, ZNF43, ABCCI1, ARFGEF2, BIRC6, CTT2, MED10, NER, Pika, PKD2R, PKD1, PTMA, PVR3L, RANBP9, RS6G, SUPH4, TMEM88B, TSE2N2, TTN, TYR, U3P34, WHSC1, ZCCHC11, CDC27, CDC27, FAM120A, FAM35B, FILIP1, HUB7L, NO3B, PHF19, XIRP2 |
| 2 I        | 30       | Sem *                            | NA        | 24                                    | 7             | 9                           | 7               | 14                            |                                      | AGTCB2, MYO5A, OR1044, WDR91, ZNF157, CACNA1B, MDN1, REVI, SCAND3, UNG, XAF1, BSDC1, BUD13, CETP, COPR5, DCHS1, DNAJC8, KIDINS220, KL, NOL1, OSBPL5, PCDH10, PTMA, SEC23B, SUPTRH, TMEM237, UB55 |
| 2 II       | 40       | Sem *                            | NA        | 53                                    | 20            | 2                           | 1               | 21                            |                                      | AGTCB2, MYO5A, OR1044, WDR91, ZNF157, CACNA1B, MDN1, REVI, SCAND3, UNG, XAF1, BSDC1, BUD13, CETP, COPR5, DCHS1, DNAJC8, KIDINS220, KL, NOL1, OSBPL5, PCDH10, PTMA, SEC23B, SUPTRH, TMEM237, UB55 |
| 3 II       | 38       | Nsem §                           | 50        | 37                                    | 9             | 0                           | 0               | 9                             |                                      | AGTCB2, MYO5A, OR1044, WDR91, ZNF157, CACNA1B, MDN1, REVI, SCAND3, UNG, XAF1, BSDC1, BUD13, CETP, COPR5, DCHS1, DNAJC8, KIDINS220, KL, NOL1, OSBPL5, PCDH10, PTMA, SEC23B, SUPTRH, TMEM237, UB55 |
| 4 I        | 30       | Sem *                            | 80 *      | 26                                    | 5             | 0                           | 0               | 5                             |                                      | AGTCB2, MYO5A, OR1044, WDR91, ZNF157, CACNA1B, MDN1, REVI, SCAND3, UNG, XAF1, BSDC1, BUD13, CETP, COPR5, DCHS1, DNAJC8, KIDINS220, KL, NOL1, OSBPL5, PCDH10, PTMA, SEC23B, SUPTRH, TMEM237, UB55 |
| 4 II       | 30       | Nsem §                           | 40        | 31                                    | 5             | 3                           | 1               | 6                             |                                      | AGTCB2, MYO5A, OR1044, WDR91, ZNF157, CACNA1B, MDN1, REVI, SCAND3, UNG, XAF1, BSDC1, BUD13, CETP, COPR5, DCHS1, DNAJC8, KIDINS220, KL, NOL1, OSBPL5, PCDH10, PTMA, SEC23B, SUPTRH, TMEM237, UB55 |
| 5 II       | 26       | Nsem §                           | 30        | 47                                    | 16            | 0                           | 0               | 16                            |                                      | AGTCB2, MYO5A, OR1044, WDR91, ZNF157, CACNA1B, MDN1, REVI, SCAND3, UNG, XAF1, BSDC1, BUD13, CETP, COPR5, DCHS1, DNAJC8, KIDINS220, KL, NOL1, OSBPL5, PCDH10, PTMA, SEC23B, SUPTRH, TMEM237, UB55 |

Abbreviations: Sem, seminoma; Nsem, non-seminoma; NA, not available.

* Pure seminoma.
‡ Familial aggregation of TGCT.
§ Non-seminoma independent of seminoma components.
¶ 50% lymphocytes in tumor tissue.
The relative proportion of base substitution mutations of eight bilateral TGCTs (exome sequencing series). 1Average relative proportion of base substitution mutations across all tumors.
this study and because whole-genome sequencing was not performed. Given that driver mutations, critical for tumorigenesis, occur before PGC separation, we expected to find at least some identical mutations in the tumor pairs. The possibility of mutations occurring in two different PGCs before separation and the migration of these two cells to different genital ridges cannot be excluded. However, we find this unlikely as PGCs may increase their number by 500-fold during migration [29]. On arrival at the genital ridges, the PGCs are renamed GCs, which are still sexually indifferent and susceptible to alterations in their tightly controlled microenvironment [2]. As separation and lateral migration toward the genital ridges is seen from gestational weeks 5 to 6 [30], we suggest that PGCs/GCs transform into intratubular germ cell neoplasia unspecified after this point of time.

In two reports, identical KIT mutations (all in exon 17, codon 816 or 823) were revealed in both testicles in 13/15 and 3/8 evaluable pairs of bilateral TGCT, suggesting that the mutations had occurred in PGCs

Table 3. Mutations in KIT Identified from the Extended TGCT Series Analyzed by Direct Sanger Sequencing

| Sample ID | Exon | Position | Amino Acid Change |
|-----------|------|----------|-------------------|
| 21 TC2 *  | 11   | 1727 T>C | L576P             |
| 38 TC1 *  | 11   | 1727 T>C | L576P             |
| 14 TC2 *  | 17   | 2446 G>C | D816H             |
| 57 TC1 †  | 17   | 2447 A>C | D816A             |
| 13 TC2 *  | 17   | 2447 A>T | D816V             |
| 15 TC2 *  | 17   | 2447 A>T | D816V             |
| 28 TC1 *  | 17   | 2447 A>T | D816V             |
| 39 EGCT ‡ | 17   | 2447 A>T | D816V             |
| 66 TC2 *  | 17   | 2466 T>G | N822K             |
| 25 TC1 †  | 17   | 2466 T>G | N822K             |

Abbreviation: TC1/TC2, first/second tumor of a bilateral TGCT pair.

* Patient with bilateral metachronous TGCT (>2 months before subsequent TGCT).
† Patient with bilateral synchronous TGCT (<2 months before subsequent TGCT).
‡ Patient with EGCT and unilateral TGCT.

Figure 2. The two somatic non-synonymous mutations in exons 21 and 22 of PDGFRα validated by direct Sanger sequencing and their spatial relationship to KIT on chromosome band 4q12. The single base substitutions, both replacing guanine by cytosine, are marked by blue arrows. The chromosomal location of KIT is included to demonstrate that PDGFRα is located adjacently upstream to KIT.

Figure 3. In utero migration and separation of PGCs. According to this embryogenesis model, the absence of identical somatic mutations in matched pairs of bilateral TGCTs supports separate clonal development and initiation of tumorigenesis after the PGC population has migrated and separated into the gonadal ridges.
before their arrival at the genital ridges [7,10]. Consequently, the hypothesis of a monoclonal origin of bilateral TGCT was proposed [10]. However, as mutations in KIT exons 11 and 17 are found in about 10% to 40% of testicular seminomas [7–9,31–35], primarily in codon 816 of exon 17, several of the reported KIT mutations among matched pairs of bilateral TGCT may have occurred by coincidence. Furthermore, as the high mutational frequencies of KIT in bilateral TGCTs in these two reports are not verified in other studies, the results should be interpreted with caution [8,9,33,36].

There is an ongoing debate whether somatic mutations of KIT in TGCT predict the risk of contralateral disease [7–10,36]. We hereby present mutational data of KIT from the largest number of bilateral TGCTs hitherto reported, finding that the mutational frequency among bilateral seminomas in our study is in line with the previously reported frequency among unilateral seminomas [7–9,31–35]. Thus, our data imply that mutations in KIT are inapt as predictors for development of bilateral TGCT.

This is the first study presenting exome sequencing data from TGCT, reporting 87 somatic non-synonymous mutations potentially linked to TGCT development. To our knowledge, these mutations have not formerly been identified in TGCT [25]. In a comprehensive TGCT Sanger sequencing study, analyzing point mutations in protein kinases, a remarkably low frequency of mutations was identified [11]. From exome sequencing of intracranial germ cell tumors, occurring typically near the time of puberty, a mean of nearly six non-synonymous mutations per tumor has been found [12]. According to a recent review of genome-wide sequencing studies, presenting the number of somatic non-synonymous mutations per tumor across various cancer types (coverage depth: median 88.5, range 20-304, 22/27 data sets with available data), our data establish TGCT as the adult solid tumor with the lowest number of base level mutations (Figure 4 and Supplementary Table S4) [5]. In fact, the number of somatic non-synonymous mutations in TGCT is more similar to pediatric than adult cancers. In the above data sets and in our study, the downstream analysis pipelines were highly overlapping, whereas estimation and reporting of the average sequence coverage, optimally performed across all targeted regions, were not always as conservative as in our study. In tumors of self-renewing tissues, the cumulative number of cell renewals, and to some extent the patient’s age, is associated with the amount of somatic mutations [37]. Although adult male germ cells are indeed highly proliferating, they reside in an arrested, pre-meiotic state until puberty [38]. Therefore,
in TGCT patients, typically diagnosed during early adulthood, a far shorter period of cumulative germ cell renewals than reflected by the chronological age may explain the correspondingly low mutational frequency among TGCT and pediatric cancers.

Surprisingly, the relative proportion of C→A/G→T and C→T/G→A base substitutions in TGCT appears higher and lower, respectively, compared to most other cancer types included in the TCGA pan-cancer analysis [39]. The significance of this finding remains to be settled.

Tumor II of patient 2 had two novel somatic non-synonymous SBS in PDGFRA, encoding the platelet-derived growth factor receptor α. PDGFRA have indeed been found overexpressed in TGCT and a functional impact of PDGFRA signaling in TGCT angiogenesis and growth has been indicated [40-42]. Thus, activating somatic mutations in PDGFRA could represent potential molecular targets in treatment of TGCT patients with metastatic disease refractory to cisplatin-based chemotherapy. Interestingly, PDGFRA and KIT, both encoding class III receptor tyrosine kinases involved in cell survival, migration, and proliferation, are located adjacent on chromosome band 4q12 [33,43]. Only base level somatic mutations in KIT, not PDGFRA, have so far been identified in TGCT [25]. In our study, the two somatic non-synonymous mutations in PDGFRA were identified in exons 21 and 22, encoding the end fragment of the intracellular tyrosine kinase and the fragment next to the carboxy-terminal part, respectively [44]. PDGFRA has been identified as a cancer driver in several cancer diseases with no particular mutational hotspot region [6]. Even though our in silico analysis by Mutation Assessor did not add functional support, we cannot rule out mutated PDGFRA as a possible driver of TGCT pathogenesis.

Non-synonymous mutations in S UPT 6 H were identified in two different tumors from the exome-sequencing series. SUPT6H is known as a regulator of RNA polymerase II transcriptional elongation, chromatin structure, estrogen receptor activity, and cellular differentiation [45]. Of the present somatic non-synonymously mutated genes identified in this study, a significant association between deletion and down-regulation in TGCT has formerly been revealed in, e.g., PBX4 and WHSC1 [40,46]. PBX4 has been annotated as a homeodomain protein and is found highly expressed in mouse testis during the first meiotic prophase of spermatocytes [47]. WHSC1 has been reported as a significant cancer gene, linked to multiple myeloma through chromosomal translocation and found expressed during embryogenesis, although mainly in adult testis and thymus [48].

According to the primary aim of this study, we used a high sensitivity mutation calling algorithm, MuTect, to identify any potential mutations identical among pairs of bilateral TGCTs [19,49,50], also those occurring with low allele frequencies. Thus, false positive mutations were inevitably disclosed using this strategy. However, the high sensitivity approach underscores our conclusion of a remarkably low mutation rate in TGCT. To determine whether mutated loci were adequately covered, the listed mutations were dichotomized according to the default coverage sufficiency threshold in the MuTect algorithm (Supplementary Tables S2A and S2B) [19]. Thus, the significance of less covered mutations should be interpreted with caution.

Bilateral TGCT and sporadic, unilateral TGCT have been found to have similar genome profiles, suggesting that unilateral and bilateral TGCTs develop through alterations of common cellular pathways [51–53]. Thus, we anticipate that the mutations identified in our study are also relevant to the pathogenesis of unilateral TGCT.

In conclusion, we find evidence for independent development of the two TGCTs in patients with bilateral disease. We further rank TGCT as the least mutated tumor type among all adult solid malignancies sequenced to date. Finally, we provide novel insights into the genomic landscape of TGCT and unravel potentially targetable oncogenes of TGCT pathogenesis, such as mutated PDGFRA.

Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.neo.2014.12.005.

Acknowledgements
We thank Merete Hektøen of the Department of Cancer Prevention, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital for her assistance in the isolation of DNA. We are grateful to Ellen Helleslyt, Mette S. Førsund, Don Trinh, and Liv Inger Hæseth of the Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital for their logistic and technical assistance with tissue samples. We also thank the following participating hospitals/laboratories for their invaluable contribution with FFPE tissue samples in the present project: Buskerud Hospital Trust, Innlandet Hospital Trust, Laboratory for Pathology Inc, Nordland Hospital Trust, Oslo University Hospital (Department of Pathology at Aker, Rikshospitalet and Ullevål), Southern Norway Hospital Trust, Stavanger Hospital Trust, Telemark Hospital Trust, University Hospital of North Norway, Vestfold Hospital Trust, and Østfold Hospital Trust.

References

[1] Znaor A, Lorret-Tieulent J, Jemal A, and Bray F (2014). International variations and trends in testicular cancer incidence and mortality. Eur Urol 65, 1095–1106.
[2] Looijenga LHJ, Gillis AJM, Stoop H, Biermann K, and Oosterhuis JW (2011). Dissecting the molecular pathways of (testicular) germ cell tumour pathogenesis; from initiation to treatment-resistance. Int J Androl 34, 234–251.
[3] Larsen WJ (1997). Gametogenesis, Fertilization and the First Week. In: Strauss M, Staff V, Terry D, editors. Human Embryology. New York: Churchill Livingstone; 1997. p. 1–4.
[4] Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, and Getz G (2014). Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495–501.
[5] Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, and Kinzler KW (2013). Cancer genome landscapes. Science 339, 1546–1558.
[6] Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Elliot K, Shmulevich I, Sander C, and Stuart JM (2013). The cancer genome atlas project. Nat Genet 45, 1113–1120.
[7] Biermann K, Gøke F, Nettersons D, Eckert D, Zhou H, Kahl P, Gashaw I, Schohe L, and Büttner R (2007). c-KIT is frequently mutated in bilateral germ cell tumours and down-regulated during progression from intratubular germ neoplasia to seminoma. J Pathol 213, 311–318.
[8] Coffey J, Linger R, Pugh J, Dudakia D, Sokal M, Easton DF, Timothy Bishop D, Straton M, Huddar R, and Repley EA (2008). Somatic KIT mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: report of 220 tumors and review of literature. Genes Chromosomes Cancer 47, 491–499.
[9] Sakuma Y, Matsukuma S, Yoshihara M, Sakurai S, Nishii M, Kishida T, Kubota D, Schorle H, and Büttner R (2007). c-KIT is frequently mutated in bilateral germ cell tumours and down-regulated during progression from intratubular germ cell neoplasia to seminoma. J Pathol 213, 311–318.
[10] Coffee J, Linger R, Pugh J, Dudakia D, Sokal M, Easton DF, Timothy Bishop D, Straton M, Huddar R, and Repley EA (2008). Somatic KIT mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: report of 220 tumors and review of literature. Genes Chromosomes Cancer 47, 34–42.
[11] Sakuma Y, Matsukuma S, Yoshihara M, Sakurai S, Nishii M, Kishida T, Kubota Y, Nagashima Y, Inayama Y, and Sasaki T, et al (2008). Mutations of c-kit gene in bilateral testicular germ cell tumours in Japan. Cancer Lett 259, 119–126.
[12] Looijenga H, de Leeuw H, van Oooshoot M, van Garp RJH, Stoop H, Gillis AJ, de Gouveia Brazao CA, Weber RF, Kierles VWJ, and van Dijk J, et al (2003). Stem cell factor receptor (c-KIT) cDNA 816 mutations predict development of bilateral testicular germ-cell tumors. Cancer Res 63, 6764–6768.
[13] Bignell G, Smith R, Hunter C, Stephens P, Davies H, Greenman C, Teague J, Butler A, Edkins S, and Stevens C, et al (2006). Sequence analysis of the protein kinase gene family in human testicular germ-cell tumors of adolescents and adults. Genes Chromosomes Cancer 45, 42–46.
